FDG-PET predicts response to chemo in Hodgkin's disease
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
Dr. Andrea Gallamini and colleagues in Italy and Denmark enrolled 260 advanced Hodgkin's lymphoma patients scheduled to receive six cycles of chemotherapy. Patients underwent F-18 FDG-PET imaging before the first and after the second chemo cycle. Those with positive and negative FDG-PET results at the second chemo cycle recorded a two-year progression-free survival rate of 12.8% and 95%, respectively (J Clin Oncol 2007;25[24]:3746-3752).
The study shows that FDG-PET can be a useful prognostic tool that will help sort patients into appropriate management paths, researchers said.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
